| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
19,560,000 |
| Market
Cap: |
203.82(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.89 - $14.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.3 |
| Insider 3/6 Months : 21.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Solid Biosciences is engaged in curing Duchenne muscular dystrophy (Duchenne), a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are Co.'s gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Co.'s SGT-001 and SGT-003 vectors are derived from a naturally occurring, non-pathogenic virus called adeno-associated virus, which were selected for their ability to enter skeletal, diaphragm and cardiac muscle tissues.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
4,314,873 |
4,314,873 |
4,314,873 |
| Total Buy Value |
$0 |
$23,861,248 |
$23,861,248 |
$23,861,248 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
462 |
35,539 |
35,539 |
37,990 |
| Total Sell Value |
$4,772 |
$126,957 |
$126,957 |
$144,031 |
| Total People Sold |
1 |
7 |
7 |
8 |
| Total Sell Transactions |
1 |
9 |
9 |
13 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ultragenyx Pharmaceutical Inc. |
10% Owner |
– – • |
2020-10-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,825,797 |
|
157% |
|
| Ganot Ilan |
CEO & President |
• • – |
2020-08-13 |
4 |
S |
$2.44 |
$730 |
I/I |
(299) |
3,483 |
|
-172% |
|
| Ganot Ilan |
CEO & President |
• • – |
2020-08-12 |
4 |
OE |
$0.00 |
$0 |
I/I |
800 |
3,737 |
|
- |
|
| Ganot Ilan |
CEO & President |
• • – |
2020-07-28 |
4 |
S |
$2.42 |
$26,910 |
D/D |
(11,124) |
1,148,007 |
|
-54% |
|
| Herscha Lynette |
Chief Legal Officer |
• – – |
2020-07-28 |
4 |
S |
$2.42 |
$12,438 |
D/D |
(5,141) |
160,859 |
|
-54% |
|
| Schneider Joel Solomon Zev |
Chief Technology Officer |
• – – |
2020-07-28 |
4 |
S |
$2.42 |
$9,776 |
D/D |
(4,041) |
284,115 |
|
-54% |
|
| Ziolkowski Jennifer Lynn |
CFO, Treasurer & Asst. Secy |
• – – |
2020-07-28 |
4 |
S |
$2.42 |
$8,687 |
D/D |
(3,591) |
327,609 |
|
-54% |
|
| Morris Carl Ashley |
Chief Scientific Officer |
• – – |
2020-07-28 |
4 |
S |
$2.42 |
$8,689 |
D/D |
(3,591) |
290,959 |
|
-54% |
|
| Ganot Ilan |
CEO & President |
• • – |
2020-07-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,500 |
1,159,131 |
|
- |
|
| Herscha Lynette |
Chief Legal Officer |
• – – |
2020-07-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,000 |
166,000 |
|
- |
|
| Schneider Joel Solomon Zev |
Chief Technology Officer |
• – – |
2020-07-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,500 |
288,156 |
|
- |
|
| Ziolkowski Jennifer Lynn |
CFO, Treasurer & Asst. Secy |
• – – |
2020-07-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,500 |
331,200 |
|
- |
|
| Morris Carl Ashley |
Chief Scientific Officer |
• – – |
2020-07-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,500 |
294,550 |
|
- |
|
| Morris Carl Ashley |
Chief Scientific Officer |
• – – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
283,050 |
|
- |
|
| Ziolkowski Jennifer Lynn |
CFO, Treasurer & Asst. Secy |
• – – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
319,700 |
|
- |
|
| Schneider Joel Solomon Zev |
Chief Technology Officer |
• – – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
276,656 |
|
- |
|
| Herscha Lynette |
Chief Legal Officer |
• – – |
2020-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
150,000 |
|
- |
|
| Schneider Joel Solomon Zev |
Chief Technology Officer |
• – – |
2020-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
201,656 |
|
- |
|
| Morris Carl Ashley |
Chief Scientific Officer |
• – – |
2020-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
208,050 |
|
- |
|
| Ziolkowski Jennifer Lynn |
CFO, Treasurer & Asst. Secy |
• – – |
2020-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
244,700 |
|
- |
|
| Herscha Lynette |
Chief Legal Officer |
• – – |
2020-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
75,000 |
|
- |
|
| Ganot Ilan |
CEO & President |
• • – |
2020-02-14 |
4 |
D |
$3.15 |
$923 |
I/I |
(293) |
2,937 |
|
- |
|
| Ganot Ilan |
CEO & President |
• • – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
I/I |
800 |
3,230 |
|
- |
|
| Ganot Ilan |
CEO & President |
• • – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
2,430 |
2,430 |
|
- |
|
| Koppel Adam |
Director |
– • – |
2019-07-30 |
4 |
A |
$4.65 |
$8,749,998 |
I/I |
1,881,720 |
3,871,164 |
|
- |
|
131 Records found
|
|
Page 4 of 6 |
|
|
0.42 (4.2%) 
